Gefitinib and erlotinib are cancer drugs which have a common chemical backbone structure, and they are commonly used as EGFR-tyrosine kinase inhibitors in lung carcinoma (Tarceva et al., 2005; Xu et al., 2010; Chen et al., 2013). The gene discussed is EGFR; the disease is lung carcinoma.